Atopic Dermatitis - Unmet needs and market opportunities

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-03-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader interviews, Datamonitor has identified a high level of unmet need in atopic dermatitis treatment and believe that a number of market opportunities exist


Scope

  • Understand opinion leaders' views on hot issues in the atopic dermatitis market
  • Assess the key unmet medical needs and identify specific opportunities in the atopic dermatitis market
  • Examine epidemiological data for the prevalence of atopic dermatitis in the seven major markets (US, Japan, France, Germany, Italy, Spain, UK)
  • Explore the current atopic dermatitis pipeline and identify leading products in development


    • Report Highlights
    About 40 million patients suffer from atopic dermatitis in the seven major markets. There is a high level of unmet need and market opportunities exist for safer systemic therapies and effective drugs for itch. However, high drug cost will be a significant barrier to entry to the market and companies must also increase focus on patient education.

    Future entrants to the atopic dermatitis market will benefit from the strategies used by Novartis for Elidel such as a rapid global rollout and broad marketing campaign. Approval across all possible patient segments will ensure greatest sales potential. Choice of topical formulation is another important issue that companies must address.

    The late stage atopic dermatitis pipeline is empty and lacks innovation. In contrast, there are a number of Phase II products looking to fill the gap in the market for effective non-steroidal therapies, left by Protopic and Elidel. Despite a need for systemic therapies, Datamonitor expects the overall demand for topical therapies will remain high.


    Reasons to Purchase

  • Review available treatments and understand major treatment controversies such as the safety of topical calcineurin inhibitors.
  • Identify opportunities in the atopic dermatitis market and learn which strategies should be considered for success of future market entrants.
  • Gain insight into the direction of future research for atopic dermatitis and learn what opinion leaders think of current pipeline products.

    • Table of Contents

    Other users found this report page using the following search terms: dermatitis allergy dermatitis atopic market unmet needs need protopic eczema opportunity corticosteroids

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.